Drug intelligence / Profile preview

DYN-R0

Development stage: Preclinical
Lead developer: Dynomics
Modality: Small Molecules

Overview

DYN-R0 is an investigational small molecule being developed by Dynomics for the treatment of cardiomyopathies associated with the PLN-R14del mutation. The PLN-R14del mutation in the phospholamban (PLN) gene is a known genetic driver of inherited dilated cardiomyopathy (DCM) and arrhythmogenic cardiomyopathy, leading to impaired calcium homeostasis and progressive cardiac dysfunction. DYN-R0 is currently in the discovery and lead optimization stage, representing a targeted approach to address the specific molecular pathology underlying this genetic form of heart disease.

Beyond the preview

Go deeper on DYN-R0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DYN-R0.

Explore the full profile